CL2007002682A1 - Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer. - Google Patents

Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.

Info

Publication number: CL2007002682A1
Authority: CL; Chile
Prior art keywords: compounds; methylpiridopirimidinone; cancer; pharmaceutical composition; cell growth
Prior art date: 2006-09-15

Application number

CL200702682A

Other languages

English (en)

Inventor

Hengmiao Cheng

Dilip Bhumralkar

Klaus Ruprecht Dress

Jacqui Elizabet Hoffman

Mary Catherine Johnson

Robert Steven Kania

Phuong Thi Quy Le

Michell David Nambu

Mason Alan Pairish

Michael Bruno Plewe

Khanh Tuan Tran

Original Assignee

Pfizer Products Inc Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-15

Filing date

2007-09-14

Publication date

2008-04-04

2007-09-14 Application filed by Pfizer Products Inc Sa filed Critical Pfizer Products Inc Sa

2008-04-04 Publication of CL2007002682A1 publication Critical patent/CL2007002682A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)

CL200702682A 2006-09-15 2007-09-14 Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer. CL2007002682A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US84506506P	2006-09-15	2006-09-15
US94785207P	2007-07-03	2007-07-03
US95262807P	2007-07-30	2007-07-30

Publications (1)

Publication Number	Publication Date
CL2007002682A1 true CL2007002682A1 (es)	2008-04-04

Family

ID=38859750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702682A CL2007002682A1 (es)	2006-09-15	2007-09-14	Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.

Country Status (41)

Country	Link
US (3)	US7696213B2 (es)
EP (1)	EP2074122B9 (es)
JP (1)	JP4718637B2 (es)
KR (1)	KR101099926B1 (es)
CN (1)	CN101573358B (es)
AP (1)	AP2710A (es)
AR (1)	AR062785A1 (es)
AT (1)	ATE514695T1 (es)
AU (1)	AU2007297212B8 (es)
BR (1)	BRPI0716749B8 (es)
CA (1)	CA2663401C (es)
CL (1)	CL2007002682A1 (es)
CR (1)	CR10662A (es)
CU (1)	CU23783B7 (es)
CY (1)	CY1111911T1 (es)
DK (1)	DK2074122T5 (es)
DO (1)	DOP2009000039A (es)
EA (1)	EA016388B1 (es)
ES (1)	ES2366489T3 (es)
GE (1)	GEP20115306B (es)
GT (1)	GT200700077A (es)
HN (1)	HN2007000267A (es)
HR (1)	HRP20110621T2 (es)
IL (1)	IL197243A (es)
MA (1)	MA30709B1 (es)
ME (1)	MEP8009A (es)
MX (1)	MX2009002927A (es)
MY (1)	MY146420A (es)
NI (1)	NI200900032A (es)
NO (1)	NO342357B1 (es)
NZ (1)	NZ575167A (es)
PE (1)	PE20080670A1 (es)
PL (1)	PL2074122T3 (es)
PT (1)	PT2074122E (es)
RS (2)	RS20090104A (es)
SI (1)	SI2074122T1 (es)
TN (1)	TN2009000085A1 (es)
TW (1)	TWI334353B (es)
UY (1)	UY30588A1 (es)
WO (1)	WO2008032162A1 (es)
ZA (1)	ZA200901477B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY146420A (en)	2006-09-15	2012-08-15	Pfizer Prod Inc	Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
DK2139484T3 (da) *	2007-04-10	2013-10-21	Exelixis Inc	Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
AU2008239596B2 (en) *	2007-04-11	2013-08-15	Exelixis, Inc.	Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
CA2729914A1 (en) *	2008-07-11	2010-01-14	Novartis Ag	Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
WO2010022126A1 (en)	2008-08-20	2010-02-25	Schering Corporation	Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5731976B2 (ja)	2008-08-20	2015-06-10	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
CA2734487A1 (en)	2008-08-20	2010-02-25	Southern Research Institute	Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734489C (en) *	2008-08-20	2016-11-08	Southern Research Institute	Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201018685A (en) *	2008-09-30	2010-05-16	Exelixis Inc	Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
JP5775171B2 (ja)	2010-12-16	2015-09-09	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	三環系ｐｉ３ｋ阻害剤化合物及びその使用方法
US8664230B2 (en) *	2011-03-17	2014-03-04	The Asan Foundation	Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) *	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EP2750675A1 (en)	2011-08-31	2014-07-09	Novartis AG	Synergistic combinations of pi3k- and mek-inhibitors
CN104829609B (zh) *	2014-02-11	2016-08-03	北大方正集团有限公司	取代的吡啶并嘧啶化合物及其制备方法和应用
WO2016015597A1 (en)	2014-07-26	2016-02-04	Sunshine Lake Pharma Co., Ltd.	Compounds as cdk small-molecule inhibitors and uses thereof
CN105330699B (zh) *	2014-08-13	2018-12-04	山东汇睿迪生物技术有限公司	一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
US10617670B2 (en)	2014-10-10	2020-04-14	Pfizer Inc.	Synergistic auristatin combinations
EP3636283A1 (en)	2015-06-04	2020-04-15	Pfizer Inc	Solid dosage forms of palbociclib
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
EP4086250B1 (en)	2016-07-06	2024-12-11	The Regents Of The University Of Michigan	Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
CU24522B1 (es)	2016-08-15	2021-06-08	Pfizer	PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS
US11241500B2 (en) *	2016-12-14	2022-02-08	Tarveda Therapeutics, Inc.	HSP90-targeting conjugates and formulations thereof
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
CN117843659A (zh)	2018-06-15	2024-04-09	詹森药业有限公司	雷帕霉素类似物和其用途
AU2019413683B2 (en) *	2018-12-28	2025-05-22	Spv Therapeutics Inc.	Cyclin-dependent kinase inhibitors
US20220220103A1 (en) *	2018-12-28	2022-07-14	Spv Therapeutics Inc.	Cyclin-dependent kinase inhibitors
US11583538B2 (en)	2019-04-08	2023-02-21	Venenum Biodesign, LLC	Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
US11819476B2 (en)	2019-12-05	2023-11-21	Janssen Pharmaceutica Nv	Rapamycin analogs and uses thereof
CN114901664B (zh) *	2020-01-10	2024-07-02	南京再明医药有限公司	吡啶酮化合物及应用
WO2022075974A1 (en) *	2020-10-06	2022-04-14	Venenum Biodesign, LLC	Cyclic trex1 inhibitors
WO2022109001A1 (en)	2020-11-18	2022-05-27	Deciphera Pharmaceuticals, Llc	Gcn2 and perk kinase inhibitors and methods of use thereof
CN118678960A (zh) *	2021-11-18	2024-09-20	安可诺瓦治疗公司	用于治疗癌症的方法和组合物
AU2024286830A1 (en)	2023-06-08	2025-12-04	Nimbus Wadjet, Inc.	Wrn inhibitors
WO2025137599A1 (en) *	2023-12-21	2025-06-26	Nimbus Wadjet, Inc.	Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264437A (en) *	1992-03-20	1993-11-23	Syntex (U.S.A.) Inc.	Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
PT790997E (pt)	1994-11-14	2000-06-30	Warner Lambert Co	6-aril pirido¬2,3-d\|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica
CN1177960A (zh) *	1995-03-10	1998-04-01	圣诺菲药品有限公司	6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en)	1997-02-04	1999-07-20	Sepracor Inc.	Synthesis of terfenadine and derivatives
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
KR20000070751A (ko)	1997-02-05	2000-11-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
GB9904932D0 (en)	1999-03-04	1999-04-28	Glaxo Group Ltd	Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
CA2394525A1 (en)	2000-01-27	2001-08-02	Warner-Lambert Company	Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
JP2003528101A (ja)	2000-03-06	2003-09-24	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	５−アルキルピリド［２，３−ｄ］ピリミジンチロシンキナーゼ阻害剤
EP1277738B1 (en)	2000-04-27	2011-03-30	Astellas Pharma Inc.	Condensed heteroaryl derivatives
AU2002233706C1 (en)	2001-02-26	2005-12-22	Tanabe Seiyaku Co., Ltd.	Pyridopyrimidine or naphthyridine derivative
US7019002B2 (en) *	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
KR20060111716A (ko)	2002-01-22	2006-10-27	워너-램버트 캄파니 엘엘씨	2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
JP2003321472A (ja)	2002-02-26	2003-11-11	Takeda Chem Ind Ltd	Ｇｒｋ阻害剤
RU2004133811A (ru)	2002-04-19	2005-04-20	Смитклайн Бичам Корпорейшн (US)	Новые соединения
MXPA04010983A (es)	2002-05-06	2005-02-14	Genelabs Tech Inc	Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c.
JP2004083587A (ja)	2002-08-06	2004-03-18	Tanabe Seiyaku Co Ltd	医薬組成物
US7098332B2 (en) *	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja)	2002-12-24	2004-07-22	Pfizer Inc	置換６，６−ヘテロ二環式誘導体
US20050009849A1 (en)	2003-01-03	2005-01-13	Veach Darren R.	Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en)	2003-04-02	2004-10-21	Imclone Systems Incorporated	4-fluoroquinolone derivatives and their use as kinase inhibitors
JP2007504283A (ja)	2003-05-20	2007-03-01	ザリージェンツオブザユニバーシティオブカリフォルニア	β−アミロイド斑に作用物質を結合させる方法
RU2317296C2 (ru)	2003-07-11	2008-02-20	Уорнер-Ламберт Компани Ллс	Изетионатная соль селективного ингибитора cdk4
EP1660087A2 (en)	2003-07-22	2006-05-31	Janssen Pharmaceutica N.V.	Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4989233B2 (ja)	2004-02-14	2012-08-01	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
EP1718645A1 (en)	2004-02-18	2006-11-08	Warner-Lambert Company LLC	2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
EP1740184A1 (en)	2004-03-30	2007-01-10	Pfizer Products Incorporated	Combinations of signal transduction inhibitors
WO2005105097A2 (en)	2004-04-28	2005-11-10	Gpc Biotech Ag	Pyridopyrimidines for treating inflammatory and other diseases
US20080255162A1 (en) *	2004-05-04	2008-10-16	Warner-Lambert Company Llc	Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
WO2005117980A1 (en)	2004-06-04	2005-12-15	Pfizer Products Inc.	Method for treating abnormal cell growth
CA2575804A1 (en)	2004-08-26	2006-03-02	Boehringer Ingelheim International Gmbh	Pteridinones used as plk (polo like kinase) inhibitors
US7608594B2 (en)	2004-11-03	2009-10-27	University Of Kansas	Novobiocin analogues as anticancer agents
WO2006065703A1 (en)	2004-12-13	2006-06-22	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en)	2004-12-23	2006-06-29	Pfizer Inc	C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
HRP20130902T1 (hr) *	2005-10-07	2013-11-08	Exelixis Inc.	PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
US8247408B2 (en) *	2005-10-07	2012-08-21	Exelixis, Inc.	Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP1872922A1 (en) *	2006-06-27	2008-01-02	Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO	Method and apparatus for manufacturing a polymeric article
CA2658725A1 (en)	2006-08-16	2008-02-21	Exelixis, Inc.	Using pi3k and mek modulators in treatments of cancer
MY146420A (en)	2006-09-15	2012-08-15	Pfizer Prod Inc	Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
MX2009009786A (es) *	2007-03-14	2009-09-24	Exelixis Inc	Inhibidores de la via de hedgehog.
AU2008239596B2 (en)	2007-04-11	2013-08-15	Exelixis, Inc.	Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
TW201018685A (en)	2008-09-30	2010-05-16	Exelixis Inc	Pyridopyrimidinone inhibitors of PI3Kα and mTOR
JP2013525308A (ja) *	2010-04-16	2013-06-20	キュリス，インコーポレイテッド	Ｋ−ｒａｓ変異を有する癌の治療

2007
- 2007-09-03 MY MYPI20091013A patent/MY146420A/en unknown
- 2007-09-03 PT PT07804890T patent/PT2074122E/pt unknown
- 2007-09-03 JP JP2009527908A patent/JP4718637B2/ja active Active
- 2007-09-03 CN CN2007800342100A patent/CN101573358B/zh not_active Expired - Fee Related
- 2007-09-03 EP EP07804890.7A patent/EP2074122B9/en active Active
- 2007-09-03 RS RSP-2009/0104A patent/RS20090104A/sr unknown
- 2007-09-03 AP AP2009004790A patent/AP2710A/xx active
- 2007-09-03 RS RS20110379A patent/RS51927B/sr unknown
- 2007-09-03 AU AU2007297212A patent/AU2007297212B8/en not_active Ceased
- 2007-09-03 NZ NZ575167A patent/NZ575167A/en not_active IP Right Cessation
- 2007-09-03 DK DK07804890.7T patent/DK2074122T5/da active
- 2007-09-03 CA CA2663401A patent/CA2663401C/en not_active Expired - Fee Related
- 2007-09-03 KR KR1020097005342A patent/KR101099926B1/ko not_active Expired - Fee Related
- 2007-09-03 ME MEP-80/09A patent/MEP8009A/xx unknown
- 2007-09-03 HR HRP20110621TT patent/HRP20110621T2/hr unknown
- 2007-09-03 AT AT07804890T patent/ATE514695T1/de active
- 2007-09-03 ES ES07804890T patent/ES2366489T3/es active Active
- 2007-09-03 BR BRPI0716749A patent/BRPI0716749B8/pt not_active IP Right Cessation
- 2007-09-03 EA EA200970207A patent/EA016388B1/ru not_active IP Right Cessation
- 2007-09-03 MX MX2009002927A patent/MX2009002927A/es active IP Right Grant
- 2007-09-03 SI SI200730715T patent/SI2074122T1/sl unknown
- 2007-09-03 GE GEAP200711157A patent/GEP20115306B/en unknown
- 2007-09-03 WO PCT/IB2007/002578 patent/WO2008032162A1/en not_active Ceased
- 2007-09-03 PL PL07804890T patent/PL2074122T3/pl unknown
- 2007-09-12 UY UY30588A patent/UY30588A1/es not_active Application Discontinuation
- 2007-09-13 AR ARP070104059A patent/AR062785A1/es not_active Application Discontinuation
- 2007-09-13 PE PE2007001238A patent/PE20080670A1/es not_active Application Discontinuation
- 2007-09-13 GT GT200700077A patent/GT200700077A/es unknown
- 2007-09-13 US US11/854,999 patent/US7696213B2/en not_active Expired - Fee Related
- 2007-09-14 TW TW096134605A patent/TWI334353B/zh not_active IP Right Cessation
- 2007-09-14 CL CL200702682A patent/CL2007002682A1/es unknown
- 2007-09-17 HN HN2007000267A patent/HN2007000267A/es unknown
2009
- 2009-02-25 IL IL197243A patent/IL197243A/en active IP Right Grant
- 2009-03-02 ZA ZA200901477A patent/ZA200901477B/xx unknown
- 2009-03-11 DO DO2009000039A patent/DOP2009000039A/es unknown
- 2009-03-13 TN TN2009000085A patent/TN2009000085A1/fr unknown
- 2009-03-13 CU CU20090040A patent/CU23783B7/es not_active IP Right Cessation
- 2009-03-13 MA MA31707A patent/MA30709B1/fr unknown
- 2009-03-13 NI NI200900032A patent/NI200900032A/es unknown
- 2009-03-13 CR CR10662A patent/CR10662A/es unknown
- 2009-03-18 NO NO20091141A patent/NO342357B1/no not_active IP Right Cessation
2010
- 2010-02-09 US US12/702,937 patent/US8273755B2/en not_active Expired - Fee Related
2011
- 2011-07-20 CY CY20111100714T patent/CY1111911T1/el unknown
2012
- 2012-08-16 US US13/587,825 patent/US8633204B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PE20080670A1 (es)	2008-06-14
JP2010503653A (ja)	2010-02-04
HRP20110621T2 (hr)	2013-12-06
TWI334353B (en)	2010-12-11
US7696213B2 (en)	2010-04-13
BRPI0716749A2 (pt)	2014-02-18
US8633204B2 (en)	2014-01-21
HK1138589A1 (en)	2010-08-27
US20120309775A1 (en)	2012-12-06
CN101573358B (zh)	2012-05-30
PL2074122T3 (pl)	2011-10-31
BRPI0716749B8 (pt)	2021-05-25
DK2074122T5 (da)	2014-03-17
US20100137279A1 (en)	2010-06-03
EP2074122B9 (en)	2013-09-11
AP2710A (en)	2013-07-30
RS51927B (sr)	2012-02-29
NO20091141L (no)	2009-03-31
ES2366489T3 (es)	2011-10-20
SI2074122T1 (sl)	2011-10-28
EA016388B1 (ru)	2012-04-30
ZA200901477B (en)	2010-07-28
NO342357B1 (no)	2018-05-14
UY30588A1 (es)	2008-05-02
AU2007297212A1 (en)	2008-03-20
MY146420A (en)	2012-08-15
KR20090040389A (ko)	2009-04-23
US20080090801A1 (en)	2008-04-17
TN2009000085A1 (fr)	2010-08-19
JP4718637B2 (ja)	2011-07-06
GT200700077A (es)	2009-08-03
WO2008032162A1 (en)	2008-03-20
GEP20115306B (es)	2011-10-10
PT2074122E (pt)	2011-08-24
CA2663401A1 (en)	2008-03-20
CY1111911T1 (el)	2015-11-04
AP2009004790A0 (en)	2009-04-30
MEP8009A (en)	2011-12-20
MA30709B1 (fr)	2009-09-01
ES2366489T9 (es)	2013-12-27
RS20090104A (sr)	2010-06-30
NZ575167A (en)	2010-10-29
CN101573358A (zh)	2009-11-04
CR10662A (es)	2009-04-17
AR062785A1 (es)	2008-12-03
CU20090040A7 (es)	2011-07-11
ATE514695T1 (de)	2011-07-15
US8273755B2 (en)	2012-09-25
DK2074122T3 (da)	2011-08-15
HN2007000267A (es)	2011-02-25
MX2009002927A (es)	2009-03-31
CU23783B7 (es)	2012-02-15
BRPI0716749B1 (pt)	2020-10-06
EP2074122B1 (en)	2011-06-29
EA200970207A1 (ru)	2009-08-28
CA2663401C (en)	2011-07-12
TW200820972A (en)	2008-05-16
NI200900032A (es)	2010-05-14
AU2007297212B8 (en)	2011-04-28
DOP2009000039A (es)	2015-12-15
KR101099926B1 (ko)	2011-12-28
IL197243A0 (en)	2009-12-24
IL197243A (en)	2013-07-31
AU2007297212B2 (en)	2011-04-14
WO2008032162A8 (en)	2009-03-26
EP2074122A1 (en)	2009-07-01
HRP20110621T1 (hr)	2011-09-30

Publication	Publication Date	Title
CL2007002682A1 (es)	2008-04-04	Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
UY32659A (es)	2010-12-31	Pirazinilpirazoles
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2008000691A1 (es)	2008-09-12	Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
CL2007000311A1 (es)	2008-01-25	Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
LTC2187879I2 (lt)	2018-10-25	Farmacinė kompozicija, apimanti gliukopiranozil-pakeistojo benzeno darinį
CL2007003470A1 (es)	2008-08-22	Compuestos derivados de urea; composicion farmaceutica que comprende a dichos compuestos; y su uso como antibacterianos.
CL2008002319A1 (es)	2009-01-02	Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI1006825A2 (pt)	2019-04-24	compostos pró-neurogênicos
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000754A1 (es)	2008-10-24	Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
PT1976506T (pt)	2019-10-15	Extratos de plantas que contêm canabinoides como agentes neuroprotetores
CL2007002617A1 (es)	2008-05-16	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
CL2007002377A1 (es)	2008-04-04	Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
CL2007002888A1 (es)	2008-05-30	Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular.
HN2008001723A (es)	2010-12-27	Nitrilos espirociclicos como inhibidores de proteasa
GT201000047A (es)	2012-03-22	Mejoras en compuestos organicos o relacionadas con los mismos
CL2008000029A1 (es)	2008-04-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008001323A1 (es)	2009-05-29	Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI0812845A2 (pt)	2014-12-09	Método para a preparação de uma composição compreendendo um absorvedor de uv orgânico insolúvel micronizado.
CL2007001919A1 (es)	2008-05-16	Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.
BRPI0818323A2 (pt)	2017-05-16	composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
CL2008000645A1 (es)	2008-10-24	Compuestos derivados de benzotiofenos sustituidos en 2-heteroarilo y derivados de benzofuranos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer, sindrome de down.